Clinical Trials Logo

Clinical Trial Summary

The purpose of this research study is to assess the efficacy and safety of ABP 215 compared to Bevacizumab in Chinese patients with advanced non-small cell lung cancer (NSCLC).


Clinical Trial Description

Approximately 170 subjects will be randomized 1:1 in approximately 40 sites in China. This study consists of a screening period of up to 28 days, followed by a treatment period of 18 weeks, and an end of study visit 3 weeks after the last dose of investigational product or study-specified chemotherapy. After randomization, subjects will receive investigational product at a dose of 15 mg/kg administered every 3 weeks for 6 cycles followed by at least 4 and no more than 6 cycles of carboplatin and paclitaxel chemotherapy every 3 weeks. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04466917
Study type Interventional
Source Amgen
Contact
Status Withdrawn
Phase Phase 3
Start date May 15, 2021
Completion date November 13, 2022

See also
  Status Clinical Trial Phase
Active, not recruiting NCT04413201 - AFAMOSI: Efficacy and Safety of Afatinib Followed by Osimertinib Compared to Osimertinib in Patients With EGFRmutated/T790M Mutation Negative Nonsquamous NSCLC Phase 4
Active, not recruiting NCT04447118 - Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy Phase 3
Completed NCT05261438 - Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC
Recruiting NCT03755869 - Study of Anlotinib in Non-squamous NSCLC Patients Who Failed First-Line(ALTER-L020) Phase 4
Not yet recruiting NCT05782426 - Study of Polymeric Micellar Paclitaxel, Platinum Combined With Sindilizumab Injection for Advanced Non-squamous NSCLC Phase 2
Recruiting NCT05751187 - Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC Patients Phase 2
Terminated NCT02454842 - Study for Treatment With TH-4000 (Tarloxotinib) in Epidermal Growth Factor Receptor (EGFR) Mutant, T790M-negative Non-small Cell Lung Cancer (NSCLC) Patients Phase 2
Not yet recruiting NCT06206850 - Neo-Bio-ADAURA: A Phase II Study to Evaluate Mechanisms of Resistance to Neoadjuvant Osimertinib Phase 2